Methods of weaning preterm babies <30 weeks gestation off CPAP: a multicentre randomised controlled trial

David A Todd, A Wright, M Broom, M Chauhan, S Meskell, C Cameron, A M Perdomi, M Rochefort, L Jardine, A Stewart, B Shadbolt

ABSTRACT

Background: Controversy exists whether different continuous positive airway pressure (CPAP) weaning methods influence time to wean off CPAP, CPAP duration, oxygen duration, Bronchopulmonary Dysplasia (BPD) or length of admission.

Aims: In a multicentre randomised controlled trial, the authors have primarily compared CPAP weaning methods impact on time to wean off CPAP and CPAP duration and secondarily their effect on oxygen duration, BPD and time of admission.

Methods: Between April 2006 and October 2009, 177 infants <30 weeks gestational age (GA) who fulfilled stability criteria on CPAP were randomised to one of the three CPAP weaning methods (M).

M1: Taken ‘OFF’ CPAP with the view to stay ‘OFF’.

M2: Cycled on and off CPAP with incremental time ‘OFF’.

M3: As with M2, cycled on and off CPAP but during ‘OFF’ periods were supported by 2 mmHg nasal cannula at a flow of 0.5 l/min.

Results: Based on intention to treat analysis, there was no significant difference in mean GA or birthweight between the groups [27.1±1.4, 26.9±1.6 and 27.3±1.5 (weeks±1SD) and 888±247, 987±249 and 1015±257 (grams±1SD), respectively]. Primary outcomes showed M1 produced a significantly shorter time to wean from CPAP (11.3±3.4, 19.4±1.3 [days±1SD]) and CPAP duration (24.4±0.1, 38.6±0.1, 30.5±0.1 [days±1SD]) p<0.0001, respectively). All the secondary outcomes were significantly shorter with M1, (oxygen duration; 24.1±1.5, 45.8±2.2, 34.1±2.0 [days±1SD] p<0.0001, BPD: 7/56 (12.5%), 29/69 (42%), 10/52 (19%) p=0.011 and length of admission: 58.5±0.1, 73.8±0.1, 69.5±0.1 [days±1SD]) p<0.0001, respectively).

Conclusion: Method 1 significantly shortens CPAP weaning time, CPAP duration, oxygen duration, BPD and admission time.

INTRODUCTION

Continuous positive airway pressure (CPAP) has been used in preterm babies as a mode of respiratory support since the 1970s and is now used in most NICUs.1–5 Subsequently, it has been shown that CPAP may reduce the need for invasive intubation and ventilation, reduce apnoea of prematurity and postextubation atelectasis. Early use of CPAP reduces the incidence of Bronchopulmonary Dysplasia (BPD (defined as an oxygen requirement at 36 weeks corrected gestational age)) and the need for home oxygen.5–11

There are several ways of delivering CPAP including head chamber, facemask, nasal prongs and endotracheal tubes.5–8 Research and clinical experience have shown that nasal CPAP with nasal prongs is the most efficient way of delivering continuous distending pressure (CDP) to the alveoli.5–8 Once infants are stabilised and breathing adequately on CPAP, the intention of discontinuing support with CPAP reduces the following:

Length of weaning time and time on CPAP
Oxygen duration and BPD
Duration of stay in the neonatal intensive care unit

What we already know

1. Most premature infants require nasal CPAP as a primary or secondary treatment.
2. Criteria to wean off CPAP and when to reinstate CPAP have not been established.
3. There is very little evidence on the best methods of weaning babies off CPAP.

What this study adds

1. Using the set stability and failure criteria of the study, taking babies off CPAP with the intention of discontinuing support with CPAP reduces the following:

Length of weaning time and time on CPAP
Oxygen duration and BPD
Duration of stay in the neonatal intensive care unit

Aims

The primary aims were to determine whether different CPAP weaning methods affect (1) time to wean off CPAP and (2) CPAP duration.

The secondary aims were to determine whether different CPAP weaning methods affect (1) oxygen duration and BPD (defined as requiring oxygen at 36 weeks corrected GA to maintain oxygen saturations >86%) and (2) length of admission.
METHODS

The CPAP weaning trial was registered with the Australian trials network (Perinatal Trials registration number ACTRN01260600155594 (registered 20/4/2006)) and was approved by each of the Hospitals Research Ethics Committee.

A Data Monitoring Committee (DMC) oversaw the conduct and results of the trial. The trial sites included (1) Canberra Hospital (Co-ordinating centre) which commenced recruiting in January 2007 (2) Westmead Hospital (Sydney) which commenced recruiting in April 2006 (3) the Royal Brisbane and Women’s Hospital which commenced recruiting in July 2008. Between April 2006 and October 2009, all premature infants <30 weeks GA who were treated with CPAP from birth or required nasal CPAP secondarily following extubation were considered for inclusion in this randomised controlled trial (RCT).

Enrolled premature infants were randomly allocated to one of the three methods of weaning CPAP. Recruitment was completed with prior consent from the parents and occurred once the infants were approaching the ‘stability criteria’ (figure 1). Exclusion criteria included the following: (1) CPAP for <24 h; (2) parents refused consent or weaning already commenced without consent; (3) need for surgery; (4) transferred to other hospital; (5) oxygen requirements >25%; (6) infant <750 g at time of randomisation; (7) congenital abnormalities; (8) >grade 2 intraventricular haemorrhage (IVH); (9) subsequently died.

Routine clinical management was provided for all premature infants <30 weeks GA with CPAP pressure and oxygen requirement adjusted as directed by the medical team. Only once the babies were stable on a CPAP pressure of 4–6 cmH2O for ≥24 h and they had satisfied the ‘stability criteria’ were babies randomised to a weaning method.

Babies were stratified by trial site and GA (<28 weeks vs 28–29 weeks) and a ratio of 1:1:1 was used by DiscoverQuick’s artificially intelligent randomisation engine to allocate premature infants to the weaning method within the strata. The trial was initially started at one site using a manual ‘simple’ randomisation approach (sealed envelopes) but this site converted to the web-based method once the second hospital began recruiting.

The three methods were as follows:

- Method 1 (M1): CPAP was taken ‘OFF’ and the premature infant remained in crib oxygen or air with a view to stay off CPAP. If the infant failed without CPAP support (figure 2: ‘failure criteria’), they were recommenced ‘ON’ CPAP at the level of CPAP when taken ‘OFF’ for at least 48 h and the infant did not trial off again until the stability criteria was again satisfied.

- Method 2 (M2): CPAP was weaned gradually by cycling between intervals of periods of time ‘OFF’ followed by a fixed period of 6 h ‘ON’ CPAP. When ‘OFF’ CPAP, the baby remained in crib oxygen or air as required. The period of time ‘OFF’ was gradually increased (2–4 h...
Leading article

Once the baby was able to tolerate 16 h ‘OFF’ CPAP an attempt was made to stop CPAP at the next period off. If the infant met the ‘failure criteria’ the baby was re-commenced ‘ON’ CPAP for 6 h or until the ‘stability criteria’ was met.

Method 3 (M3): CPAP was weaned ‘OFF’ in a similar way to ‘M2’, but the premature infants in this group were given humidified (water bubbler) nasal cannula (2 mm) oxygen/air (using an oxygen blender) during their time ‘OFF’ with a flow rate of 0.5 l/min. This flow rate of 0.5 l/min with a 2 mm nasal cannula was adequate to be used with the water bubbler for humidification but did not generate a CPAP pressure. When M3 infants came off CPAP, they were continued on the nasal cannula for a further 24 h prior to complete removal of support.

The premature infant completed their method by successfully trialling OFF respiratory support for a period of 5 days. The centralised monitoring team reviewed the data for quality and completeness.

STUDY NUMBERS AND STATISTICS

Sample size calculations based on data (time to wean off CPAP) from 1997–2004 extracted from one of the neonatal units in the trial indicated that to reduce the time spent on CPAP by 15%, a total sample size of 195 premature infants was required (65 in each group) to achieve 80% power and significance levels ($\alpha$) of 0.05 or less.

A planned interim analysis was to be undertaken after 3 years. As a result of the interim analysis, the data-monitoring committee stopped the study. The DMC reviewed the interim analysis and concluded that the results clearly demonstrated effect sizes and within-group variations that were not going to vary from the interim analysis if recruitment was to continue. As a result, the study was stopped 1 year early.

Analyses of the data were performed on (1) all premature infants randomised to the trial (intention to treat (primary analysis)) first by analysing the data with adjustment for gender differences and Apgar scores and (2) on premature infants who completed the trial (per protocol (did not violate study protocol)). Those premature infants who were excluded in the per protocol analysis were those who (1) consultant withdrawal, (2) parental withdrawal, (3) transferred to other hospital or surgery, (4) died after randomisation.

In addition to descriptive analyses, multivariate analyses were performed using generalised linear models adjusting for gender and Apgar scores at 1 and 5 min. The models used linear scale response or Tweedie with log link, depending on the outcome measure’s distribution. Bonferroni post-hoc pair-wise comparisons were carried out to adjust for repeated testing. For the analysis on the number of times taken to come off CPAP in M1; Mann–Whitney U tests were used to test the significance of gender and Spearman rho correlations were used to examine the effect of GA. Analyses were performed in SPSS version 17.0.

RESULTS

A total of 412 premature infants <30 weeks GA were identified during the recruitment period, 177 premature infants were enrolled in the study and were randomised as shown in figure 3 and table 1. Of the 177 enrolled, 154 premature infants completed the trial (figure 3). The numbers in the M2 study group were slightly larger (table 1) as a result of the initial random selection process not using permuted blocks but simple randomisation (sealed envelopes done

Figure 3  Total preterm babies, those eligible and enrolled in the trial (intention to treat (ITT) and per protocol (PP)).

Table 1  Baseline characteristics by CPAP weaning method (n=177)

<table>
<thead>
<tr>
<th></th>
<th>M1 (n=56)</th>
<th>M2 (n=69)</th>
<th>M3 (n=52)</th>
<th>Sig</th>
</tr>
</thead>
<tbody>
<tr>
<td>GA (weeks)</td>
<td>27.1±1.4↑</td>
<td>26.9±1.6↑</td>
<td>27.3±1.5</td>
<td>NS</td>
</tr>
<tr>
<td>BWt (g)</td>
<td>988±247↑</td>
<td>987±249↑</td>
<td>1015±257↑</td>
<td>NS</td>
</tr>
<tr>
<td>F:M (M%)</td>
<td>37:19 (34%)</td>
<td>27:42 (64%)</td>
<td>25:27 (52%)</td>
<td>p=0.01</td>
</tr>
<tr>
<td>Apgar 1</td>
<td>5 (3–6)↑</td>
<td>4 (3–6)</td>
<td>6 (4–7)*</td>
<td>p=0.006</td>
</tr>
<tr>
<td>Apgar 5</td>
<td>7 (6–8)↑</td>
<td>7 (6–8)</td>
<td>8 (7–9)*</td>
<td>p=0.01</td>
</tr>
<tr>
<td>Surfactant (Y/N)</td>
<td>53:3 (95%)</td>
<td>61:8 (88%)</td>
<td>46:6 (88%)</td>
<td>NS</td>
</tr>
<tr>
<td>CGA start wean (weeks)</td>
<td>29.6±1.7↑</td>
<td>30.5±2.3↑</td>
<td>29.7±1.9↑</td>
<td>NS</td>
</tr>
<tr>
<td>CWt start wean (g)</td>
<td>1014±38↑</td>
<td>1112±34</td>
<td>1074±40</td>
<td>NS</td>
</tr>
</tbody>
</table>

*Significantly higher than M1 & M2 p<0.01.
†Mean±1SD
‡Median (range)

BWt, birthweight; CGA, corrected GA; CWt, corrected Wt; GA, gestational age.
outside of DiscoverQuick) and the stopping of the study before DiscoverQuick could achieve a balance. There were no significant differences in GA or birthweight (Bwt), although there was a significant difference in gender with a higher proportion of females in M1 (table 1, p<0.01); and a significant difference in Apgar scores, with the premature infants in M3 having significantly higher scores at 1 and 5 min (table 1). There were no significant differences in corrected GA or current Wt between the groups at the time of randomisation and commencement of weaning (table 1).

The intention to treat analyses of the outcome indicators after adjusting for gender and Apgar scores are shown in table 2. Based on primary outcomes, time to wean CPAP and CPAP duration were significantly reduced with M1. Based on secondary outcomes, oxygen duration and incidence of BPD and length of admission were significantly shorter using M1 compared to the other methods.

Analysis as per protocol on the 154 premature infants who completed the trial found similar results (results not displayed). On reviewing data for premature infants in M1 who completed the trial per protocol 32% (16/50) came off CPAP on the first attempt, 42% (21/50) required 2–3 attempts to come off and the remaining 28% (14/50) took 4–13 attempts to come off CPAP. Males tended to take more attempts to come off CPAP than females (median attempts to come off CPAP=5.2/ M:F, this was not significant). As expected, the more immature premature infants took significantly more attempts to come off than the more mature premature infants (median attempts to come off CPAP: 24/25 weeks=3, 26 weeks=3, 27 weeks=3.5, 28 weeks=2 and 29 weeks=1 attempts p<0.001). Babies more mature at 28–29 weeks GA took an average of 2.4±1.9 or median of 2 attempts to come off CPAP, while the more immature <28 weeks GA took an average of 3.9±2.9 or a median of three attempts.

### DISCUSSION

In this RCT on CPAP weaning consideration was made of both when and how to wean premature infants OFF CPAP. Trial setup included construction of the trial ‘stability criteria’ and ‘failure criteria’: that is when to take premature infants OFF CPAP and when to put the babies back ON CPAP. The trial analysis included comparison of three methods of weaning premature infants OFF CPAP. No major critical incidents were recorded during the RCT although one infant in M1, two infants in M2 and one infant in M3 died from causes not related to the trial.

A previous study demonstrated that in infants <34 weeks GA who had their CPAP discontinued for 6 h have an increased oxygen requirement, increased respiratory rate and increased number of apnoea and bradycardias but take less time to come off CPAP.15 This study did not actually assess CPAP weaning methods but described the events when coming off CPAP and is consistent with M1 in the current trial.15 Two trials comparing weaning methods from a flow driver have shown that weaning from the initial CPAP pressures are better achieved by gradually decreasing the CPAP pressure rather than by slowly cycling the time off CPAP at that initial pressure.16 17 Soe et al found that in the more immature infants 24–27 weeks GA there was a trend towards less hospital days and less oxygen dependency at 36 weeks in the pressure reduction arm while there was no difference between the groups in the more mature infants 28–31 weeks GA.17 The confounding problem with both these trials is that the babies were taken off the CPAP at initial CPAP pressures. It is thus possible that the babies’ respiratory system was still immature and unstable when taken off CPAP or the pressures were too high to be taken off.16 17 Not withstanding these differences, in the current study, it has also been demonstrated that cycling is not necessary when the infant is taken off CPAP once reaching the stability criteria. A recent trial of weaning CPAP in infants >27 weeks GA has shown that replacing the CPAP with nasal cannula at a flow of 21/min increases the days of oxygen, increases the duration of respiratory support but causes no difference regarding success of weaning.10 Singh et al also used low flow nasal cannulae during times off CPAP but this use was not shown to improve the time to wean and is similar to the current study.16 Low-flow and high-flow nasal cannulae are now being used more frequently for both weaning and as a replacement for nasal CPAP.18 20–24 More research is needed with these alternative forms of respiratory support.

It remains a contentious issue as to when to wean premature infants off CPAP and when to return them to CPAP. Literature acknowledges the Columbia method and many units continue to only wean CPAP once the infant is breathing air.5 21 22 Some units also include parameters such as weight or corrected GA before considering weaning.22 Thus knowing when to discontinue CPAP and when to replace CPAP has been poorly defined with most using an ‘ad hoc’ method.12 15 This study has utilised formulated ‘stability’ and ‘failure’ criteria based on previous studies and literature.5 12 15 22 Others have used similar stability criteria to the current study but with higher oxygen requirements of <30% oxygen.18 While the currently used ‘stability’ criteria in this trial may have been adequate for the more mature infants as they required only 2.4±1.9 attempts to come off CPAP it may not be so for the more immature <28 weeks GA as they required an average of 3.9±2.9 attempts. Having a ‘stability’ criterion (guidelines) in itself may be superior to using the ‘ad hoc’ method. Similarly having a ‘failure’ criterion and knowing when to put the infants back on CPAP may not have been adequate for the more immature infants and this may need to be modified in future trials. Despite the range of attempts to come ‘OFF’ CPAP, this RCT showed significant reductions in secondary outcome such as oxygen duration and BPD using M1.

Previous studies have found in infants <30 weeks GA an incidence of BPD of 15% in a hospital based population25 and an incidence of 26.9% for a multicentre cohort.26 While for the more immature infants <28 weeks GA an incidence of 12.5% 29/69 (42%) in an incidence of BPD of 12.5%.
immatute infants <28 weeks GA an incidence varies from 17–69% depending on the early pulmonary dysfunction and/or infection.27–30 In those <29 weeks, the incidence is somewhat similar at 29–55%.31 Although not powered specifically to study BPD, this study has shown that infants <30 weeks GA using M1 for weaning CPAP have a 12.5% incidence of BPD (table 2) with an oxygen duration of around 24 days compared to an oxygen duration of 46 and 34 days in the other methods, respectively (table 2). A possible mechanism is that 48 h on CPAP, once failed, has resulted in or allowed for full recruitment of the lungs and thus ensured the stability of the airways. In premature infants weaned by cycling off and on CPAP (M2) in short periods without oxygen/air support via nasal cannula, their lungs may not be fully recruited following the short period on CPAP and they may have partial atelectasis when the CPAP is removed. The cycle of recruitment and atelectasis may lead to airway damage and hence more BPD. In M3 where the infant was supported by low flow during times off, there was also a reduction in BPD although not in time and this requires further investigations.

Length of admission in the Neonatal unit and discharge to either home or to level 2 (special care units) was also significantly reduced in M1. This may have major health benefits and reduced health costs not only in the short term but also on a long-term basis. Premature infants especially with BPD are known to have long-term problems including home oxygen and further long term issues such as reactive airways and increased asthma symptoms with more hospitalisations.32 Follow-up is essential as there have been very little data addressing their respiratory and neurodevelopmental outcomes.4

In conclusion, this RCT on CPAP weaning has shown that in conjunction with the study stability and failure criteria, using M1 for weaning OFF CPAP significantly reduces time to wean CPAP, CPAP duration, oxygen duration, BPD and length of admission. Weaning CPAP using M1 had an impact on the intensity, costs and length of neonatal intensive care and may improve the long-term outcome in these small preterm infants. It is acknowledged that further trials are necessary to confirm these results.

Contributors Dr David Todd conceived the idea of the RCT on weaning preterm infants from CPAP. Other members of the group recruited patients, collected and input data. Dr Bruce Shadbolt set up the DiscoverQuick database, randomisation process and performed the statistical analysis.

Acknowledgements The authors thank all the clinicians who have helped in this study especially those who have aided in recruiting and data collection. Specifically, the authors thank Dr Sinivas Ramakrishnan, Dr Chetan Pandit, Ms Kelly Cameron and Mrs Jane Baird. The authors also thank the data monitoring committee (DMC) consisting of Ass Prof Graham Reynolds (Chair), Prof William Tarnow Mordi, Ass Prof Abdul-Latif Mohamed, Dr Tim McDonald and Mrs Jeni Williams. The terms of reference for the DMC were set up in accordance with the DAMOCLES Study Group for clinical trial monitoring.33 Funding Funding for the CPAP weaning study was obtained from (1) Canberra Hospital, Private Practice Fund, (2) Canberra Hospital, Newborn Intensive Care Foundation and (3) Fisher and Paykel Healthcare. Funding from the 3 sources was for Research Nurse Salary, Construction and Maintenance of Tronfic Database, Postage, Some travel to present results at meetings. There was no involvement in the mechanics of the study by any of the funding sources.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Received 2 May 2011 Accepted 1 April 2012


REFERENCES

Methods of weaning preterm babies <30 weeks gestation off CPAP: a multicentre randomised controlled trial

David A Todd, A Wright, M Broom, et al.

Arch Dis Child Fetal Neonatal Ed 2012 97: F236-F240 originally published online May 18, 2012
doi: 10.1136/adc.2011-300133

Updated information and services can be found at:
http://fn.bmj.com/content/97/4/F236.full.html

These include:

References
This article cites 29 articles, 9 of which can be accessed free at:
http://fn.bmj.com/content/97/4/F236.full.html#ref-list-1

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/